Literature DB >> 7053306

Alpha1-acid glycoprotein concentration and protein binding in trauma.

D J Edwards, D Lalka, F Cerra, R L Slaughter.   

Abstract

Alpha 1-Acid glycoprotein (AAG) concentrations were measured every 2 to 3 days in eight trauma patients and seven healthy subjects for approximately 3 wk. Mean AAG concentrations in the trauma patients rose from 100 mg/dl to a peak value of 243 mg/dl at 10 to 14 days. AAG levels averaged more than 200 mg/dl at 15 to 21 days. Mean AAG concentration in healthy subjects was 70 mg/dl with little inter- or intraindividual variability. Lidocaine was added to all serum samples from four of the patients and to selected samples from all of the healthy subjects and protein binding was determined. The binding ratio (bound concentration/free concentration) correlated strongly with AAG concentration in the trauma patients (r = 0.92), in the healthy subjects (r = 0.84), and in both groups combined (r = 0.96). AAG concentration and binding ratio for each of the four patients individually also correlated (P less than 0.05 in all cases). The change in free fraction associated with this increase in AAG was approximately doubled in each patient. Similar findings with drugs commonly used in trauma patients would be expected to alter serum concentration-response relationships significantly.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7053306     DOI: 10.1038/clpt.1982.10

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  30 in total

Review 1.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

2.  Local anesthetics: a century of progress.

Authors:  J A Yagiela
Journal:  Anesth Prog       Date:  1985 Mar-Apr

3.  The effect of age on serum concentrations of albumin and alpha 1-acid glycoprotein.

Authors:  B T Veering; A G Burm; J H Souverijn; J M Serree; J Spierdijk
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

4.  Alpha 1-acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria.

Authors:  K Silamut; P Molunto; M Ho; T M Davis; N J White
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

5.  Drug-binding proteins in liver transplant patients.

Authors:  M L Huang; R Venkataramanan; G J Burckart; R J Ptachcinski; D H Van Thiel; T E Starzl
Journal:  J Clin Pharmacol       Date:  1988-06       Impact factor: 3.126

6.  Pharmacokinetics of quinidine in male patients. A population analysis.

Authors:  C N Verme; T M Ludden; W A Clementi; S C Harris
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

7.  Lack of effect of treatment with human recombinant-tumour necrosis factor (HrTNF) on the binding of quinidine to alpha 1-acid glycoprotein (AGP).

Authors:  J A Barnett; D E Brenner; P J Creaven; D Lalka
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

8.  The plasma protein binding of basic drugs.

Authors:  P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

9.  Lidocaine protein binding in preeclampsia.

Authors:  M B Bottorff; J A Pieper; B A Boucher; T J Hoon; J Ramanathan; B M Sibai
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  Changes in the concentration of serum alpha 1-acid glycoprotein in epileptic patients.

Authors:  K Morita; A Yamaji
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.